Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.

Clinical genitourinary cancer·2026
Same author

Definitive radiotherapy for non-small-cell lung cancer: current practice and future directions.

Japanese journal of radiology·2026
Same author

External control arms can validate treatment efficacy in single-arm studies.

Journal of the National Cancer Institute·2026
Same author

CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities.

Cancers·2026

相关实验视频

Updated: Jan 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

帕尔P抑制剂可以使同源重组修复能力强,耐化的前列腺癌患者受益吗? 一个元分析.

Susu Zhou1, Devashish Desai2, Noriko Kishi3

  • 1Division of Hematology and Oncology, Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, 13210, USA. zhous@upstate.edu.

Targeted oncology
|December 3, 2025
PubMed
概括

多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 改善转移性割抵抗性前列腺癌 (mCRPC) 的无进展生存期 (PFS),无论同源重组修复 (HRR) 状态如何. 基于PARPi的疗法在HRR熟练的mCRPC中显示出临床相关性,为患者选择保证了进一步的研究.

更多相关视频

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.9K
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.8K

相关实验视频

Last Updated: Jan 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.9K
Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.8K

科学领域:

  • 在瘤学瘤学.
  • 生殖尿道癌症 生殖尿道癌症
  • 前列腺癌治疗方法 前列腺癌治疗方法

背景情况:

  • PARP 抑制剂 (PARPi) 已被确立为HRR缺乏的mCRPC.
  • 在HRR熟练的mCRPC中,PARPi的有效性还没有得到很好的定义.

研究的目的:

  • 在HRR熟练的mCRPC中评估PARPi的疗效.
  • 在HRR熟练和HRR缺乏的mCRPC群体之间比较疗效.

主要方法:

  • 对临床试验进行系统的文献搜索 (PubMed,Embase,Cochrane,科学网,会议记录).
  • 在HRR熟练和HRR缺陷的mCRPC中对PARPi疗效的单臂和双向元分析.
  • 根据治疗方案进行子组分析.

主要成果:

  • 单臂元分析:PSA应答18% (HRR熟练) 与46% (HRR缺乏) 相比;12个月的PFS42%与57%.
  • 双对分析:PARPi在HRR熟练 (HR 0.69) 和HRR缺陷 (HR 0.60) 的mCRPC中显著改善了PFS.
  • 在分析中,HRR熟练和HRR缺陷组之间的疗效没有显著差异.

结论:

  • 无论HRR状态如何,PARPi可以改善mCRPC中的PFS.
  • 基于PARPi的疗法在HRR熟练的mCRPC中提供了令人鼓舞的PFS益处.
  • 需要进一步的生物标志物研究来优化PARPi选择和治疗策略.